Viral Hepatitis

You have full text access to this OnlineOpen article

Entecavir treatment for up to 5 years in patients with hepatitis B e antigen–positive chronic hepatitis B†‡§

  1. Ting-Tsung Chang1,¶,*,
  2. Ching-Lung Lai2,
  3. Seung Kew Yoon3,
  4. Samuel S. Lee4,
  5. Henrique Sergio M. Coelho5,
  6. Flair Jose Carrilho6,
  7. Fred Poordad7,
  8. Waldemar Halota8,
  9. Yves Horsmans9,
  10. Naoky Tsai10,
  11. Hui Zhang11,
  12. Daniel J. Tenney11,
  13. Ricardo Tamez12,
  14. Uchenna Iloeje11

Article first published online: 4 JAN 2010

DOI: 10.1002/hep.23327

Issue

Hepatology

Hepatology

Volume 51, Issue 2, pages 422–430, February 2010

Additional Information

How to Cite

Chang, T.-T., Lai, C.-L., Kew Yoon, S., Lee, S. S., Coelho, H. S. M., Carrilho, F. J., Poordad, F., Halota, W., Horsmans, Y., Tsai, N., Zhang, H., Tenney, D. J., Tamez, R. and Iloeje, U. (2010), Entecavir treatment for up to 5 years in patients with hepatitis B e antigen–positive chronic hepatitis B. Hepatology, 51: 422–430. doi: 10.1002/hep.23327

Author Information

  1. 1

    Medical College, National Cheng Kung University, Tainan, Taiwan, ROC

  2. 2

    Queen Mary Hospital, Hong Kong, China

  3. 3

    Kangnam St. Mary Hospital, The Catholic University of Korea, Seoul, Korea

  4. 4

    Foothills Provincial General Hospital, University of Calgary, Calgary, Canada

  5. 5

    Hospital Universitario Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil

  6. 6

    Department of Gastroenterology, University of São Paulo School of Medicine, São Paulo, SP, Brazil

  7. 7

    Department of Hepatology and Liver Transplantation, Cedars-Sinai Medical Center, Los Angeles, CA

  8. 8

    Department of Infectious Diseases and Hepatology, Nicolaus Copernicus University, Bydgoszcz, Poland

  9. 9

    Department of Hepatology and Gastroenterology, Cliniques St Luc, Brussels, Belgium

  10. 10

    University of Hawaii, Honolulu, HI

  11. 11

    Bristol-Myers Squibb Co. (BMS), Research and Development, Wallingford, CT

  12. 12

    Bristol-Myers Squibb Co., Research and Development, Princeton, NJ

  1. fax: +886-6-209-5233

*138 Sheng-Li Road, Tainan, 70428, Taiwan, Republic of China

  1. †

    Potential conflicts of interest: Ting-Tsung Chang: Research support from Bristol-Myers Squibb; Ching-Lung Lai: Research support and consultancy fees from Bristol-Myers Squibb. SeungKew Yoon: Nothing to disclose. Samuel S. Lee: Consultancy fees from Roche, Gilead, Bristol-Myers Squibb, and Novartis. Speakers' bureau for Roche, Gilead, and Bristol-Myers Squibb. Henrique Sergio M Coelho: Nothing to disclose. Flair Jose Carrilho: Research support from Bristol-Myers Squibb. Fred Poordad: Research support, speakers' bureau fees, and consultancy fees from Bristol-Myers Squibb. Waldemar Halota: Nothing to disclose. Yves Horsmans: Consultancy fees from Bristol-Myers Squibb. Naoky Tsai: Research support, speakers' bureau fees, and consultancy fees from Bristol-Myers Squibb. Hui Zhang: BMS employee. Daniel J. Tenney: BMS employee. Ricardo Tamez: BMS employee. Uchenna Iloeje: BMS employee.

  2. ‡

    In addition to the authors, the following investigators participated in the study: Asia/Pacific: Nurul Akbar, Marilyn Arguillas, You-Chen Chao, Su-Kiun Chin, Kwang-Hyub Han, Simon Huang, Ian Kronborg, Alice Lee, Jacob George, Sik-To Lai, Shou-Dong Lee, Yun-Fan Liaw, Chee Chian Lim, Gin-Ho Lo, Yiu Wing Luk, George Marinos, Ismail Merican, Rosmawati Mohamed, Eng Keat Ooi, Stuart Roberts, William Sievert, Jose Sollano, Chee Kiat Tan, Judy Lao-Tan, Tawesak Tanwandee, Shun-Sheng Wu, Felix Zano. Europe and Middle East: Edward Antuch, Yucel Batur, Anna Boron-Kaczmarska, Pavel Chalupa, Isabelle Colle, Andrzej Gladysz, Barbara Gocman, Zbigniew Gonciarz, Markus H. Heim, Vasily Isakov, Ran Tur-Kaspa, Sabahattin Kaymakoglu, Wieslaw Kryczka, Jan Kuydowicz, Yoav Lurie, Tomasz Mach, Francesco Mazzotta, Roma Modrzewska, Beat Muellhaupt, Assy Nimer, Court Pedersen, Vladimir Rafalsky, Maria Raptopoulou-Gigi, Daniel Shouval, Marian Sikora, Cihan Yurdaydin, Konstantin Zhdanov. USA and Canada: Frank H. Anderson, Thomas Boyer, Robert Brown, Robert G. Gish, Anna Lok, Gerald Minuk, Raymond Rubin, Eugene Schiff, Morris Sherman. Latin America: Antonio A. Barone, Fernando Bessone, Hugo Cheinquer, Laura E. Cisneros Garza, Luiz Guilherme Costa Lyra, Hugo Fainboim, Jorge Ferrandiz, Maria Lucia Ferraz, Fernando L. Goncales, Jr, Mario Pessoa, Marcelo Silva, Ruben Terg.

  3. §

    The sponsor designed the study in collaboration with expert hepatologists. The sponsor also collected the data, monitored study conduct, performed the statistical analyses, and coordinated writing of the article with all authors.

Publication History

  1. Issue published online: 25 JAN 2010
  2. Article first published online: 4 JAN 2010
  3. Manuscript Accepted: 11 SEP 2009
  4. Manuscript Received: 4 MAR 2009

Funded by

  • Bristol-Myers Squibb

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (371K)

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Xiaoyu Liu, Xiaozhen Jiao, Qian Wu, Chengsen Tian, Renze Li, Ping Xie, A novel and efficient synthesis of Entecavir, Tetrahedron Letters, 2012,

    CrossRef

  2. 2
    Yun-Fan Liaw, Jia-Horng Kao, Teerha Piratvisuth, Henry Lik Yuen Chan, Rong-Nan Chien, Chun-Jen Liu, Ed Gane, Stephen Locarnini, Seng-Gee Lim, Kwang-Hyub Han, Deepak Amarapurkar, Graham Cooksley, Wasim Jafri, Rosmawati Mohamed, Jin-Lin Hou, Wan-Long Chuang, Laurentius A. Lesmana, Jose D. Sollano, Dong-Jin Suh, Masao Omata, Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update, Hepatology International, 2012, 6, 3, 531

    CrossRef

  3. 3
    Alexander Kuo, Robert Gish, Chronic Hepatitis B Infection, Clinics in Liver Disease, 2012, 16, 2, 347

    CrossRef

  4. 4
    Chang-jie Cai, Min-qiang Lu, Ying-hua Chen, Hui Zhao, Min-ru Li, Gui-hua Chen, Clinical study on prevention of HBV re-infection by entecavir after liver transplantation, Clinical Transplantation, 2012, 26, 2
    Direct Link:
  5. 5
    J. Wiegand, M. Kühne, P. Pradat, J. Mössner, C. Trepo, H. L. Tillmann, Different patterns of decompensation in patients with alcoholic vs. non-alcoholic liver cirrhosis, Alimentary Pharmacology & Therapeutics, 2012, 35, 12
    Direct Link:
  6. 6
    María Buti, Rosa Maria Morillas, Martín Prieto, Moisés Diago, Juan Pérez, Ricard Solà, Lucía Bonet, Antonio Palau, Milagros Testillano, Javier García-Samaniego, Manuel Rodríguez, Efficacy and safety of entecavir in clinical practice in treatment-naive Caucasian chronic hepatitis B patients, European Journal of Gastroenterology & Hepatology, 2012, 24, 5, 535

    CrossRef

  7. 7
    Wai-Kay Seto, Yasuhito Tanaka, Danny Ka-Ho Wong, Ching-Lung Lai, Noboru Shinkai, John Chi-Hang Yuen, Teresa Tong, James Fung, Ivan Fan-Ngai Hung, Man-Fung Yuen, Evidence of serologic activity in chronic hepatitis B after surface antigen (HBsAg) seroclearance documented by conventional HBsAg assay, Hepatology International, 2012,

    CrossRef

  8. 8
    S. Pol, P. Lampertico, First-line treatment of chronic hepatitis B with entecavir or tenofovir in ‘real-life’ settings: from clinical trials to clinical practice, Journal of Viral Hepatitis, 2012, 19, 6
    Direct Link:
  9. 9
    Zeng Minde, Mao Yimin, Yao Guangbi, Hou JinLin, Wang Hao, Ren Hong, Wang Yuming, Zhou Xiaqiu, Xu Daozhen, Chen Yagang, Niu Junqi, Chen Youming, Wang Yaozong, Jonathan Dixon, Keith Barker, Five years of treatment with adefovir dipivoxil in Chinese patients with HBeAg-positive chronic hepatitis B, Liver International, 2012, 32, 1
    Direct Link:
  10. 10
    Patrick Marcellin, Ferruccio Bonino, Cihan Yurdaydin, Stephanos Hadziyannis, Rami Moucari, Hans-Peter Kapprell, Vivien Rothe, Matei Popescu, Maurizia R. Brunetto, Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients, Hepatology International, 2012,

    CrossRef

  11. 11
    Ashley Brown, Zachary Goodman, Hepatitis B-associated fibrosis and fibrosis/cirrhosis regression with nucleoside and nucleotide analogs, Expert Review of Gastroenterology & Hepatology, 2012, 6, 2, 187

    CrossRef

  12. 12
    R.M. Martín Mateos, F. García-Alonso, V. Moreira Vicente, Hepatitis crónica por virus B. Historia natural y tratamiento, Medicine - Programa de Formación Médica Continuada Acreditado, 2012, 11, 9, 521

    CrossRef

  13. 13
    Calvin Q. Pan, Myron Tong, Kris V. Kowdley, Ke–Qin Hu, Ting–Tsung Chang, Ching–Lung Lai, Seung Kew Yoon, Samuel S. Lee, David Cohen, Hong Tang, Naoky Tsai, High Rates of Viral Suppression After Long-term Entecavir Treatment of Asian Patients With Hepatitis B e Antigen–Positive Chronic Hepatitis B, Clinical Gastroenterology and Hepatology, 2012,

    CrossRef

  14. 14
    Mika Kurokawa, Naoki Hiramatsu, Tsugiko Oze, Takayuki Yakushijin, Masanori Miyazaki, Atsushi Hosui, Takuya Miyagi, Yuichi Yoshida, Hisashi Ishida, Tomohide Tatsumi, Shinichi Kiso, Tatsuya Kanto, Akinori Kasahara, Sadaharu Iio, Yoshinori Doi, Akira Yamada, Masahide Oshita, Akira Kaneko, Kiyoshi Mochizuki, Hideki Hagiwara, Eiji Mita, Toshifumi Ito, Yoshiaki Inui, Kazuhiro Katayama, Harumasa Yoshihara, Yasuharu Imai, Eijirou Hayashi, Norio Hayashi, Tetsuo Takehara, Long-term effect of lamivudine treatment on the incidence of hepatocellular carcinoma in patients with hepatitis B virus infection, Journal of Gastroenterology, 2012, 47, 5, 577

    CrossRef

  15. 15
    Michael P Manns, Ulus S Akarca, Ting-Tsung Chang, William Sievert, Seung Kew Yoon, Naoky Tsai, Albert Min, Andreas Pangerl, Suzanne Beebe, Miao Yu, Suchat Wongcharatrawee, Long-term safety and tolerability of entecavir in patients with chronic hepatitis B in the rollover study ETV-901, Expert Opinion on Drug Safety, 2012, 11, 3, 361

    CrossRef

  16. 16
    Stephanos J. Hadziyannis, Dimitrios Vassilopoulos, What Should Be the Endpoints of Oral Therapy in HBeAg-positive Versus HBeAg-negative Patients with Chronic Hepatitis B, Current Hepatitis Reports, 2012, 11, 2, 65

    CrossRef

  17. 17
    Yuk-Fai Lam, Man-Fung Yuen, Wai-Kay Seto, Ching-Lung Lai, Current Antiviral Therapy of Chronic Hepatitis B: Efficacy and Safety, Current Hepatitis Reports, 2011, 10, 4, 235

    CrossRef

  18. 18
    Gillian M. Keating, Entecavir, Drugs, 2011, 71, 18, 2511

    CrossRef

  19. 19
    M. Pawłowska, W. Halota, E. Smukalska, T. Woźniakowska-Gęsicka, J. Kupś, HBV DNA suppression during entecavir treatment in previously treated children with chronic hepatitis B, European Journal of Clinical Microbiology & Infectious Diseases, 2011, 31, 4, 571

    CrossRef

  20. 20
    J. Fung, C.-L. Lai, W.-K. Seto, M.-F. Yuen, Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B, Journal of Antimicrobial Chemotherapy, 2011, 66, 12, 2715

    CrossRef

  21. 21
    Shunsuke Mori, Past hepatitis B virus infection in rheumatoid arthritis patients receiving biological and/or nonbiological disease-modifying antirheumatic drugs, Modern Rheumatology, 2011, 21, 6, 621

    CrossRef

  22. 22
    Xiao-Qin Chen, Jie-Wen Peng, Gui-Nan Lin, Mei Li, Zhong-Jun Xia, The effect of prophylactic lamivudine on hepatitis B virus reactivation in HBsAg-positive patients with diffuse large B-cell lymphoma undergoing prolonged rituximab therapy, Medical Oncology, 2011, 29, 2, 1237

    CrossRef

  23. 23
    D.M. Harnois, Entecavir treatment for up to 5years in patients with hepatitis B e antigen-positive chronic hepatitis B, Yearbook of Medicine, 2010, 2010, 473

    CrossRef

  24. 24
    D.M. Harnois, Entecavir treatment for up to 5years in patients with hepatitis B e antigen-positive chronic hepatitis B, Yearbook of Gastroenterology, 2010, 2010, 234

    CrossRef

  25. 25
    J.-P. Zarski, Influence du traitement sur l’évolution à long terme de l’hépatite chronique B, Gastroentérologie Clinique et Biologique, 2010, 34, S109

    CrossRef

  26. 26
    P. Marcellin, Le traitement a un impact positif sur l’évolution à long terme de l’hépatite chronique B, Gastroentérologie Clinique et Biologique, 2010, 34, S99

    CrossRef

  27. 27
    N. Ben Slama, S.N. Si Ahmed, F. Zoulim, Quantification de l’antigène HBs : signification virologique, Gastroentérologie Clinique et Biologique, 2010, 34, S112

    CrossRef

  28. 28
    Anna S. F. Lok, Francesco Negro, Hepatitis B and D,
    Direct Link:
View Full Article (HTML) Get PDF (371K)